Table 1.
Demographic and Clinical Characteristics of Patients
| Characteristics | n(%) |
|---|---|
| Gender | |
| Female | 124(55.6%) |
| Male | 99(44.4%) |
| Age, median | |
| <61 | 111(49.8%) |
| ≥61 | 112(50.2%) |
| Smoking history | |
| Never | 139(62.3%) |
| Ever | 29(13.0%) |
| Unrecorded | 55(24.7%) |
| Pathological stage | |
| I | 158(71.2%) |
| II | 19(8.6%) |
| III | 35(15.8%) |
| IV | 10(4.5%) |
| T stage | |
| T1 | 87(39.4%) |
| T2 | 120(54.3%) |
| T3 | 6(2.7%) |
| T4 | 8(3.6%) |
| N stage | |
| N0 | 171(78.1%) |
| N1 | 18(8.2%) |
| N2-N3 | 30(13.7%) |
| M stage | |
| M0 | 212(95.5%) |
| M1 | 10(4.5%) |
| EGFR mutation | |
| WT | 107(48.0%) |
| 19del | 56(25.1%) |
| 20ins | 4(1.8%) |
| L858R | 53(23.8%) |
| G719X | 3(1.3%) |
| ALK rearranged | |
| WT | 202(91.0%) |
| Rearranged | 20(9.0%) |
| Immunological phenotype | |
| Non–inflamed | 117(53.7%) |
| Intermediate | 71(32.6%) |
| Inflamed | 30(13.8%) |
Abbreviations: EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.